These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Changes associated with delay of mammary cancer by retinoid analogues in transgenic mice bearing c-neu oncogene. Rao GN; Ney E; Herbert RA Breast Cancer Res Treat; 1999 Dec; 58(3):241-54. PubMed ID: 10718486 [TBL] [Abstract][Full Text] [Related]
23. Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes. Amundadottir LT; Leder P Oncogene; 1998 Feb; 16(6):737-46. PubMed ID: 9488037 [TBL] [Abstract][Full Text] [Related]
24. Protein tyrosine phosphatase epsilon increases the risk of mammary hyperplasia and mammary tumors in transgenic mice. Elson A Oncogene; 1999 Dec; 18(52):7535-42. PubMed ID: 10602512 [TBL] [Abstract][Full Text] [Related]
25. Induction of mammary epithelial hyperplasias and mammary tumors in transgenic mice expressing a murine mammary tumor virus/activated c-src fusion gene. Webster MA; Cardiff RD; Muller WJ Proc Natl Acad Sci U S A; 1995 Aug; 92(17):7849-53. PubMed ID: 7544006 [TBL] [Abstract][Full Text] [Related]
26. Epithelial and fibroblast cell lines derived from a spontaneous mammary carcinoma in a MMTV/neu transgenic mouse. Campbell MJ; Wollish WS; Lobo M; Esserman LJ In Vitro Cell Dev Biol Anim; 2002 Jun; 38(6):326-33. PubMed ID: 12513120 [TBL] [Abstract][Full Text] [Related]
27. Early and multifocal tumors in breast, salivary, harderian and epididymal tissues developed in MMTY-Neu transgenic mice. Lucchini F; Sacco MG; Hu N; Villa A; Brown J; Cesano L; Mangiarini L; Rindi G; Kindl S; Sessa F Cancer Lett; 1992 Jul; 64(3):203-9. PubMed ID: 1322235 [TBL] [Abstract][Full Text] [Related]
28. An activated allele of the c-erbB-2 oncogene impairs kidney and lung function and causes early death of transgenic mice. Stöcklin E; Botteri F; Groner B J Cell Biol; 1993 Jul; 122(1):199-208. PubMed ID: 8100231 [TBL] [Abstract][Full Text] [Related]
29. Expression of an activated Notch-related int-3 transgene interferes with cell differentiation and induces neoplastic transformation in mammary and salivary glands. Jhappan C; Gallahan D; Stahle C; Chu E; Smith GH; Merlino G; Callahan R Genes Dev; 1992 Mar; 6(3):345-55. PubMed ID: 1372276 [TBL] [Abstract][Full Text] [Related]
30. Hormonal modulation of neu-induced mammary carcinogenesis: evidence against a single-step induction of mammary cancer by neu. Tai YT; Gould MN Carcinogenesis; 1995 Jul; 16(7):1455-9. PubMed ID: 7614677 [TBL] [Abstract][Full Text] [Related]
31. Inhibition of mammary carcinoma development in HER-2/neu transgenic mice through induction of autoimmunity by xenogeneic DNA vaccination. Pupa SM; Iezzi M; Di Carlo E; Invernizzi A; Cavallo F; Meazza R; Comes A; Ferrini S; Musiani P; Ménard S Cancer Res; 2005 Feb; 65(3):1071-8. PubMed ID: 15705909 [TBL] [Abstract][Full Text] [Related]
32. Keratinocyte growth factor induces mammary and prostatic hyperplasia and mammary adenocarcinoma in transgenic mice. Kitsberg DI; Leder P Oncogene; 1996 Dec; 13(12):2507-15. PubMed ID: 9000125 [TBL] [Abstract][Full Text] [Related]
33. Cooperating oncogenic events in murine mammary tumorigenesis: assessment of ErbB2, mutant p53, and mouse mammary tumor virus. Zelazny E; Li B; Anagnostopoulos AM; Coleman A; Perkins AS Exp Mol Pathol; 2001 Jun; 70(3):183-93. PubMed ID: 11417997 [TBL] [Abstract][Full Text] [Related]
34. Development of mammary hyperplasia and neoplasia in MMTV-TGF alpha transgenic mice. Matsui Y; Halter SA; Holt JT; Hogan BL; Coffey RJ Cell; 1990 Jun; 61(6):1147-55. PubMed ID: 2161707 [TBL] [Abstract][Full Text] [Related]
35. Development of hyperplasias, preneoplasias, and mammary tumors in MMTV-c-erbB-2 and MMTV-TGFalpha transgenic rats. Davies BR; Platt-Higgins AM; Schmidt G; Rudland PS Am J Pathol; 1999 Jul; 155(1):303-14. PubMed ID: 10393862 [TBL] [Abstract][Full Text] [Related]
36. Protein-tyrosine phosphatase epsilon. An isoform specifically expressed in mouse mammary tumors initiated by v-Ha-ras OR neu. Elson A; Leder P J Biol Chem; 1995 Nov; 270(44):26116-22. PubMed ID: 7592814 [TBL] [Abstract][Full Text] [Related]
37. Identification of tumorsphere- and tumor-initiating cells in HER2/Neu-induced mammary tumors. Liu JC; Deng T; Lehal RS; Kim J; Zacksenhaus E Cancer Res; 2007 Sep; 67(18):8671-81. PubMed ID: 17875707 [TBL] [Abstract][Full Text] [Related]
38. Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice. Maroulakou IG; Oemler W; Naber SP; Tsichlis PN Cancer Res; 2007 Jan; 67(1):167-77. PubMed ID: 17210696 [TBL] [Abstract][Full Text] [Related]
39. Overexpression of the colony-stimulating factor (CSF-1) and/or its receptor c-fms in mammary glands of transgenic mice results in hyperplasia and tumor formation. Kirma N; Luthra R; Jones J; Liu YG; Nair HB; Mandava U; Tekmal RR Cancer Res; 2004 Jun; 64(12):4162-70. PubMed ID: 15205327 [TBL] [Abstract][Full Text] [Related]
40. Loss of periostin/OSF-2 in ErbB2/Neu-driven tumors results in androgen receptor-positive molecular apocrine-like tumors with reduced Notch1 activity. Sriram R; Lo V; Pryce B; Antonova L; Mears AJ; Daneshmand M; McKay B; Conway SJ; Muller WJ; Sabourin LA Breast Cancer Res; 2015 Jan; 17(1):7. PubMed ID: 25592291 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]